LeMaitre Vascular (NASDAQ:LMAT) Issues FY24 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its FY24 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $1.73-1.84 for the period, compared to the consensus estimate of $1.65. The company issued revenue guidance of $212.7-217.3 million, compared to the consensus revenue estimate of $211.69 million. LeMaitre Vascular also updated its Q2 guidance to $0.45-0.50 EPS.

LeMaitre Vascular Trading Up 11.2 %

Shares of LMAT stock traded up $7.45 during trading hours on Friday, hitting $74.22. 329,984 shares of the company’s stock were exchanged, compared to its average volume of 110,751. The company has a market capitalization of $1.67 billion, a PE ratio of 49.15, a PEG ratio of 3.20 and a beta of 0.88. LeMaitre Vascular has a 12-month low of $44.27 and a 12-month high of $74.64. The business’s 50 day simple moving average is $65.93 and its 200-day simple moving average is $58.85.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 EPS for the quarter, topping the consensus estimate of $0.39 by $0.05. The firm had revenue of $53.48 million for the quarter, compared to the consensus estimate of $51.50 million. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.75%. The business’s revenue was up 13.6% compared to the same quarter last year. During the same period last year, the firm posted $0.27 earnings per share. Equities analysts anticipate that LeMaitre Vascular will post 1.77 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 30th. Shareholders of record on Thursday, May 16th will be paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.86%. The ex-dividend date is Wednesday, May 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.38%.

Wall Street Analyst Weigh In

LMAT has been the topic of several analyst reports. Stifel Nicolaus raised shares of LeMaitre Vascular from a hold rating to a buy rating and lifted their target price for the stock from $59.00 to $75.00 in a research note on Friday, April 26th. KeyCorp initiated coverage on shares of LeMaitre Vascular in a research note on Tuesday, February 6th. They issued a sector weight rating on the stock. JMP Securities lifted their target price on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the stock a market outperform rating in a research note on Friday. StockNews.com raised shares of LeMaitre Vascular from a hold rating to a buy rating in a research note on Friday. Finally, Barrington Research lifted their target price on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the stock an outperform rating in a research note on Friday. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $73.83.

Insider Buying and Selling at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 36,600 shares of the business’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $68.03, for a total transaction of $2,489,898.00. Following the sale, the chief executive officer now owns 2,187,526 shares in the company, valued at approximately $148,817,393.78. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CEO George W. Lemaitre sold 36,600 shares of the business’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $68.03, for a total transaction of $2,489,898.00. Following the sale, the chief executive officer now owns 2,187,526 shares in the company, valued at approximately $148,817,393.78. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director John A. Roush sold 7,500 shares of the business’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $69.00, for a total transaction of $517,500.00. Following the sale, the director now owns 2,278 shares in the company, valued at approximately $157,182. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 114,036 shares of company stock valued at $7,873,749. 10.79% of the stock is currently owned by company insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.